nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—adrenal gland cancer	0.524	0.54	CbGaD
Pomalidomide—ABCB1—adrenal gland cancer	0.446	0.46	CbGaD
Pomalidomide—Lenalidomide—PTGS2—adrenal gland cancer	0.00314	0.408	CrCbGaD
Pomalidomide—Lenalidomide—ABCB1—adrenal gland cancer	0.00267	0.347	CrCbGaD
Pomalidomide—Thalidomide—PTGS2—adrenal gland cancer	0.00188	0.245	CrCbGaD
Pomalidomide—CYP1A2—urine—adrenal gland cancer	0.00153	0.164	CbGeAlD
Pomalidomide—CRBN—adrenal cortex—adrenal gland cancer	0.00123	0.132	CbGeAlD
Pomalidomide—CYP3A4—urine—adrenal gland cancer	0.0011	0.119	CbGeAlD
Pomalidomide—CRBN—gonad—adrenal gland cancer	0.00102	0.109	CbGeAlD
Pomalidomide—CRBN—cardiac atrium—adrenal gland cancer	0.00102	0.109	CbGeAlD
Pomalidomide—CRBN—pituitary gland—adrenal gland cancer	0.000993	0.107	CbGeAlD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—DAXX—adrenal gland cancer	0.000913	0.0673	CbGpPWpGaD
Pomalidomide—CRBN—adrenal gland—adrenal gland cancer	0.000887	0.0953	CbGeAlD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—DAXX—adrenal gland cancer	0.000816	0.0601	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—DAXX—adrenal gland cancer	0.000753	0.0555	CbGpPWpGaD
Pomalidomide—PTGS2—adrenal cortex—adrenal gland cancer	0.000335	0.0359	CbGeAlD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—MED12—adrenal gland cancer	0.000321	0.0237	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—PRKACA—adrenal gland cancer	0.000317	0.0233	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—PTGS2—adrenal gland cancer	0.000313	0.023	CbGpPWpGaD
Pomalidomide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—adrenal gland cancer	0.000308	0.0227	CbGpPWpGaD
Pomalidomide—PTGS2—pituitary gland—adrenal gland cancer	0.00027	0.029	CbGeAlD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—PRKACA—adrenal gland cancer	0.000253	0.0186	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—DAXX—adrenal gland cancer	0.000248	0.0183	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—BAD—adrenal gland cancer	0.000244	0.018	CbGpPWpGaD
Pomalidomide—PTGS2—adrenal gland—adrenal gland cancer	0.000242	0.0259	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—DAXX—adrenal gland cancer	0.000224	0.0165	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RRM1—adrenal gland cancer	0.000208	0.0154	CbGpPWpGaD
Pomalidomide—ABCB1—adrenal cortex—adrenal gland cancer	0.000207	0.0222	CbGeAlD
Pomalidomide—TNF—Ceramide signaling pathway—BAD—adrenal gland cancer	0.000202	0.0149	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—RB1—adrenal gland cancer	0.000202	0.0149	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RB1—adrenal gland cancer	0.000187	0.0138	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—ABCB1—adrenal gland cancer	0.000183	0.0135	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—RB1—adrenal gland cancer	0.000181	0.0133	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IGF2—adrenal gland cancer	0.000179	0.0132	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1R—adrenal gland cancer	0.000173	0.0127	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IGF1R—adrenal gland cancer	0.000173	0.0127	CbGpPWpGaD
Pomalidomide—ABCB1—gonad—adrenal gland cancer	0.000171	0.0184	CbGeAlD
Pomalidomide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—adrenal gland cancer	0.000169	0.0124	CbGpPWpGaD
Pomalidomide—ABCB1—pituitary gland—adrenal gland cancer	0.000167	0.018	CbGeAlD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—adrenal gland cancer	0.000154	0.0114	CbGpPWpGaD
Pomalidomide—ABCB1—adrenal gland—adrenal gland cancer	0.000149	0.016	CbGeAlD
Pomalidomide—TNF—TWEAK Signaling Pathway—CTNNB1—adrenal gland cancer	0.000148	0.0109	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PRKACA—adrenal gland cancer	0.000148	0.0109	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—adrenal gland cancer	0.000144	0.0106	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—BRAF—adrenal gland cancer	0.000143	0.0105	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDC42—adrenal gland cancer	0.000141	0.0104	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—DAXX—adrenal gland cancer	0.000139	0.0102	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—BAD—adrenal gland cancer	0.000136	0.01	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—PRKACA—adrenal gland cancer	0.000133	0.00982	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BAD—adrenal gland cancer	0.000129	0.00954	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—adrenal gland cancer	0.000129	0.00949	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TOP2A—adrenal gland cancer	0.000129	0.00948	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—PRKACA—adrenal gland cancer	0.000126	0.00925	CbGpPWpGaD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	0.000125	0.00924	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—CTNNB1—adrenal gland cancer	0.000121	0.00893	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NR5A1—adrenal gland cancer	0.000121	0.0089	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—BAD—adrenal gland cancer	0.00012	0.00887	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—adrenal gland cancer	0.000116	0.00854	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	0.000109	0.00805	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	0.000109	0.00805	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—adrenal gland cancer	0.000107	0.00787	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CDC42—adrenal gland cancer	0.000107	0.00785	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDKN2A—adrenal gland cancer	0.000102	0.0075	CbGpPWpGaD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	0.000102	0.00749	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—DAXX—adrenal gland cancer	9.82e-05	0.00724	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	9.68e-05	0.00713	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—adrenal gland cancer	9.17e-05	0.00676	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—adrenal gland cancer	9.13e-05	0.00673	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ABCB1—adrenal gland cancer	9.01e-05	0.00664	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—RB1—adrenal gland cancer	8.82e-05	0.0065	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDC42—adrenal gland cancer	8.74e-05	0.00644	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—adrenal gland cancer	8.51e-05	0.00627	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—RB1—adrenal gland cancer	8.16e-05	0.00602	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP2A—adrenal gland cancer	7.96e-05	0.00587	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BAD—adrenal gland cancer	7.93e-05	0.00584	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—adrenal gland cancer	7.91e-05	0.00583	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MED12—adrenal gland cancer	7.26e-05	0.00535	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—adrenal gland cancer	7.25e-05	0.00534	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—adrenal gland cancer	7.06e-05	0.0052	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—adrenal gland cancer	6.87e-05	0.00506	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BRAF—adrenal gland cancer	6.77e-05	0.00499	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	6.75e-05	0.00498	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	6.71e-05	0.00494	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—adrenal gland cancer	6.56e-05	0.00483	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—adrenal gland cancer	6.29e-05	0.00464	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—adrenal gland cancer	6e-05	0.00442	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—adrenal gland cancer	5.95e-05	0.00438	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—adrenal gland cancer	5.66e-05	0.00417	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—adrenal gland cancer	5.64e-05	0.00416	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—adrenal gland cancer	5.57e-05	0.00411	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	5.47e-05	0.00403	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RB1—adrenal gland cancer	5.46e-05	0.00402	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—adrenal gland cancer	5.39e-05	0.00397	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—adrenal gland cancer	5.22e-05	0.00384	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	5.19e-05	0.00382	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—adrenal gland cancer	5.14e-05	0.00379	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	5.04e-05	0.00372	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	4.93e-05	0.00363	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDC42—adrenal gland cancer	4.49e-05	0.00331	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	4.43e-05	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	4.41e-05	0.00325	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—adrenal gland cancer	4.32e-05	0.00318	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	4.22e-05	0.00311	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	4.15e-05	0.00306	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	4.01e-05	0.00296	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—adrenal gland cancer	3.87e-05	0.00285	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	3.82e-05	0.00282	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	3.82e-05	0.00282	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SH3KBP1—adrenal gland cancer	3.78e-05	0.00278	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDHB—adrenal gland cancer	3.72e-05	0.00274	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ZNRF3—adrenal gland cancer	3.55e-05	0.00262	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	3.5e-05	0.00258	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—adrenal gland cancer	3.47e-05	0.00256	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	3.42e-05	0.00252	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—adrenal gland cancer	3.25e-05	0.0024	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—adrenal gland cancer	3.18e-05	0.00234	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	2.94e-05	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	2.94e-05	0.00216	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	2.93e-05	0.00216	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	2.73e-05	0.00201	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—adrenal gland cancer	2.67e-05	0.00197	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDHB—adrenal gland cancer	2.64e-05	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RRM1—adrenal gland cancer	2.4e-05	0.00177	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDHD—adrenal gland cancer	2.4e-05	0.00177	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	2.35e-05	0.00173	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	2.27e-05	0.00167	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SPRY2—adrenal gland cancer	2.23e-05	0.00164	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	2.16e-05	0.00159	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	2.16e-05	0.00159	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDHB—adrenal gland cancer	2.1e-05	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—adrenal gland cancer	2.06e-05	0.00152	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MEN1—adrenal gland cancer	2.04e-05	0.0015	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	1.97e-05	0.00145	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	1.93e-05	0.00143	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	1.82e-05	0.00134	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	1.82e-05	0.00134	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MED12—adrenal gland cancer	1.79e-05	0.00132	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RRM1—adrenal gland cancer	1.7e-05	0.00125	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDHD—adrenal gland cancer	1.7e-05	0.00125	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	1.66e-05	0.00122	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—adrenal gland cancer	1.63e-05	0.0012	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDHB—adrenal gland cancer	1.62e-05	0.0012	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	1.6e-05	0.00118	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.6e-05	0.00118	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKACA—adrenal gland cancer	1.56e-05	0.00115	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	1.53e-05	0.00113	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDHD—adrenal gland cancer	1.36e-05	0.000999	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RRM1—adrenal gland cancer	1.36e-05	0.000999	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDC42—adrenal gland cancer	1.32e-05	0.000973	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PRKACA—adrenal gland cancer	1.3e-05	0.00096	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	1.29e-05	0.000948	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MED12—adrenal gland cancer	1.27e-05	0.000933	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—adrenal gland cancer	1.06e-05	0.00078	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNAS—adrenal gland cancer	1.06e-05	0.000778	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RRM1—adrenal gland cancer	1.05e-05	0.000771	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDHD—adrenal gland cancer	1.05e-05	0.000771	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—adrenal gland cancer	1.04e-05	0.000764	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MED12—adrenal gland cancer	1.01e-05	0.000745	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PRKACA—adrenal gland cancer	9.24e-06	0.000681	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BAD—adrenal gland cancer	9.21e-06	0.000679	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	9.04e-06	0.000666	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—adrenal gland cancer	8.39e-06	0.000618	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MED12—adrenal gland cancer	7.8e-06	0.000575	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNAS—adrenal gland cancer	7.49e-06	0.000552	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	7.38e-06	0.000543	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	7.21e-06	0.000531	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—POMC—adrenal gland cancer	7.11e-06	0.000524	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—adrenal gland cancer	6.06e-06	0.000447	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNAS—adrenal gland cancer	5.98e-06	0.00044	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	5.87e-06	0.000432	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	5.69e-06	0.000419	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—POMC—adrenal gland cancer	5.04e-06	0.000371	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—adrenal gland cancer	4.8e-06	0.000354	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNAS—adrenal gland cancer	4.61e-06	0.00034	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	4.53e-06	0.000334	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—POMC—adrenal gland cancer	4.02e-06	0.000297	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—adrenal gland cancer	4.02e-06	0.000296	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	3.21e-06	0.000237	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—POMC—adrenal gland cancer	3.11e-06	0.000229	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	2.48e-06	0.000183	CbGpPWpGaD
